Projects per year
Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 16 Similar Profiles
Protein-Tyrosine Kinases
Medicine & Life Sciences
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Medicine & Life Sciences
Meta-Analysis
Medicine & Life Sciences
Blood Vessels
Medicine & Life Sciences
Leukemia
Medicine & Life Sciences
Endothelial Cells
Medicine & Life Sciences
Biomarkers
Medicine & Life Sciences
Atherosclerosis
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2013 2016
Etude miR-126 impliqué en oncogenèse
Muylkens, B., Graux, C., George, F. & Finet, L.
1/12/13 → …
Project: Research
Test sanguin de détection/pronostic de cancer
Popa, C., De Ronde, T., Rahier, J., D'Hondt, L., Graux, C., George, F., Finet, L. & Herzog, M.
1/12/13 → …
Project: Research
Etude de l’effet potentiel de macrophages sur la cytotoxicité de molécules chimiothérapeutiques vis-à-vis de cellules cancéreuses
Graux, C., Michiels, C. & Genin, M.
1/12/13 → 30/09/14
Project: Research
Télévie: Etude de la résistance des tumeurs aux agents utilisés en chimiothérapie : caractérisation et validation d’un gène candidat
Michiels, C., Graux, C., D'Hondt, L., George, F. & Finet, L.
1/12/13 → 30/09/16
Project: Research
Research Output 2012 2018
Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study
Bouvy, C., Wannez, A., George, F., Graux, C., Chatelain, C. & Dogné, J-M., 18 Jan 2018, In : Biomarkers in cancer. 10, p. 1179299X18781095Research output: Contribution to journal › Article
Open Access
Lymphoma, Large B-Cell, Diffuse
MicroRNAs
Longitudinal Studies
Biomarkers
Clinical Studies
Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture
Haguet, H., Douxfils, J., Mullier, F., Chatelain, C., Graux, C. & Dogne, J-M., Dec 2017.Research output: Contribution to conference › Poster
Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture
Haguet, H., Douxfils, J., Chatelain, C. J., Graux, C., Mullier, F. & Dogné, J-M., 2017, Abstract and Meeting Program of the 59th ASH Annual Meeting. Suppl 1 ed. Vol. 130. p. 1591-1591 1 p. (Blood).Research output: Contribution in Book/Catalog/Report/Conference proceeding › Conference contribution
Protein-Tyrosine Kinases
Rupture
Atherosclerosis
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions
Haguet, H., Douxfils, J., Chatelain, C. J., Graux, C., Mullier, F. & Dogné, J-M., 2017, Abstract and Meeting Program of the 59th ASH Annual Meeting. Suppl 1 ed. Vol. 130. p. 1592-1592 1 p. (Blood).Research output: Contribution in Book/Catalog/Report/Conference proceeding › Conference contribution
Protein-Tyrosine Kinases
Cell Survival
Endothelial Cells
Atherosclerosis
E-Selectin
In Vitro Effects of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells Survival and Functions
Haguet, H., Douxfils, J., Mullier, F., Chatelain, C., Graux, C. & Dogne, J-M., Dec 2017.Research output: Contribution to conference › Poster
Datasets
Risk of arterial and venous occlusive events in chronic myeloid leukemia patients treated with new generation BCR-ABL tyrosine kinase inhibitors: a systematic review and meta-analysis
Graux, C. (Contributor), Figshare, 29 Nov 2016
DOI: 10.6084/m9.figshare.4265168.v1, https://figshare.com/articles/Risk_of_arterial_and_venous_occlusive_events_in_chronic_myeloid_leukemia_patients_treated_with_new_generation_BCR-ABL_tyrosine_kinase_inhibitors_a_systematic_review_and_meta-analysis/4265168/1 and one more link, https://ndownloader.figshare.com/files/6948968 (show fewer)
Dataset
Activities 2015 2018
- 5 Oral presentation
In vitro effects of BCR-ABL TKIs on endothelial cell survival and functions
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), François Mullier (Speaker), Jean-Michel Dogne (Speaker)9 Feb 2018
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)25 Feb 2017
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML - A systematic review and meta-analysis
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)28 Apr 2016
Activity: Talk or presentation types › Oral presentation
Risk of vascular occlusive events with BCR-ABL TKIs in CML - A systematic review and meta-analysis
Hélène Haguet (Speaker), Jonathan Douxfils (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)29 Jan 2016
Activity: Talk or presentation types › Oral presentation
Risk of cardiovascular events associated with BCR-ABL TKI in leukemic population: a systematic review and meta-analysis
Jonathan Douxfils (Speaker), Hélène Haguet (Speaker), François Mullier (Speaker), Christian Chatelain (Speaker), Carlos Graux (Speaker), Jean-Michel Dogne (Speaker)Jun 2015
Activity: Talk or presentation types › Oral presentation
Thesis
Roles of extracellular vesicles and their microRNA cargo in chemotherapeutic resistance, pro-coagulant phenotype and as potential biomarkers in diffuse large B-cell lymphoma
Author: Bouvy, C., 16 Oct 2017Supervisor: Dogne, J. (Supervisor), Chatelain, C. (Co-Supervisor), Caron, N. (President), Graux, C. (Jury), Michiels, C. (Jury), Stamatopoulos, B. (External person) (Jury) & Ingrid, S. (External person) (Jury)
Student thesis: Doc types › Doctor of Biomedical and Pharmaceutical Sciences
Press / Media
Volition Creates Clinical Evaluation Committee
14/11/11 → 16/11/11
2 items of media coverage
Press/Media: Expert Comment